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INTRODUCTION
Matrix metalloproteinases (MMPs) 
are a family of calcium-dependent, 
zinc-containing endopeptidases that are 
structurally and functionally related (1). 
They are secreted in an inactive (latent) 
form, which is called a zymogen or a 
pro-MMP. These latent MMPs require 
an activation step before they are able 
to cleave extracellular matrix (ECM) 
components (1). The activity of MMPs 
is regulated by several types of inhib-
itors, of which the tissue inhibitors of 
metalloproteinases (TIMPs) are the 
most important (2). The TIMPs are 
also secreted proteins, but they may be 
located at the cell surface in association 
with membrane-bound MMPs (3). The 
balance between MMPs and TIMPs 
is largely responsible for the control 
of degradation of ECM proteins (4). 
MMPs are involved in the remodeling 
of tissues during embryonic devel-
opment, cell migration, wound healing, 
and tooth development (5–8). However, 
a deregulation of the balance between 
MMPs and TIMPs is a characteristic of 
diverse pathological conditions, such as 
rheumatoid and osteoarthritis, cancer 
progression, and acute and chronic 
cardiovascular diseases (3,9,10). To 
analyze the role of MMPs and TIMPs 
in tissue remodeling under normal and 
pathological conditions, it is important 
to have reliable detection methods. This 
review will briefly describe all known 
MMPs, their activation, and their role 
in tissue remodeling and pathology. It 
will focus on zymographical techniques 
for the analysis of MMPs and TIMPs.
THE MMP FAMILY 
The family of human MMPs consists 
of 23 different forms that are divided 
into six groups (11–14). In order to 
classify the MMPs, knowledge of their 
characteristics is essential. It has been 
shown that each MMP consists of a 
specific domain sequence with several 
domain motifs. This sequence includes 
the signal peptide, the propeptide 
domain, the catalytic domain, and the 
C-terminal hemopexin-like domain, 
which are present in almost all MMPs 
(15). However, several MMPs have 
additional domains such as a trans-
membrane or a cytoplasmic domain 
(15,16). The organization of the MMP 
domains, together with their substrate 
specificity and sequence similarity, 
define the MMP classification. Six 
groups can be distinguished (Table 1; 
subgroups 1–6). (1.) The collagenase 
group includes MMP-1, MMP-8, and 
MMP-13. These are generally able 
to cleave the interstitial collagens I, 
II, and III. Collagenases are also able 
to digest certain other ECM and non-
ECM proteins (8,12,17). (2.) The 
gelatinase group, which consists of 
MMP-2 and MMP-9, mainly digests 
gelatin, the denatured form of collagen 
(8,12). (3.) The stromelysins, MMP-3 
and MMP-10, digest ECM components 
such as collagen IV and fibronectin. 
MMP-11 is also called stromelysin-3, 
but its sequence and substrate speci-
ficity are different from that of MMP-3 
and MMP-10. Therefore, MMP-11 is 
usually placed in the heterogeneous 
subgroup (see subgroup 6) (8,12,17). 
(4.) The matrilysins, MMP-7 and 
MMP-26, which are categorized differ-
ently among the MMP subgroups by 
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several authors (4,12,18,19). Both 
matrilysins digest several ECM 
components, such as fibronectin and 
gelatin (20). They lack the C-terminal 
hemopexin-like domain present in all 
other MMPs and are therefore also 
called the minimal-domain MMPs 
(16,21). (5.) The membrane-type 
matrix metalloproteinases (MT-MMP), 
of which six forms are known, can 
digest a number of ECM proteins such 
as gelatin, fibronectin, and laminin 
(22). Moreover, most MT-MMPs can 
activate pro-MMP-2 (8,12). (6.) The 
remaining MMPs are gathered in a 
more heterogeneous subgroup because 
of their different substrate specificity, 
amino acid sequence, or domain organi-
zation. This group includes MMP-12, 
MMP-19, MMP-20, MMP-21, MMP-
23, MMP-27, and MMP-28 (8,12), 
which cleave substrates such as elastin 
and aggrecan (23,24). The classifi-
cation presented here is a general one, 
and several other classifications are 
used (4,8,12,17). The main difference 
between these classifications is the 
assignment of the matrilysins, which 
are sometimes designated separately 
or to the stromelysins or the heteroge-
neous subgroup (4,8,12,17). 
In healthy tissues, some MMPs such 
as MMP-7, MMP-19, MMP-24, MMP-
25, and MMP-26 are expressed at low 
levels (25). Many of the other MMPs, 
such as MMP-1, MMP-3, MMP-9, 
MMP-10, MMP-11, and MMP-13 are 
absent or only marginally expressed in 
normal, healthy, resting tissues. During 
repair or remodeling processes and in 
diseased or inflamed tissues, MMP 
expression is often increased (25,26). 
ACTIVATION OF MMPs
MMP activity is regulated at 
multiple levels, such as at the level of 
gene transcription and the synthesis 
of pro-MMPs. Furthermore, the 
activation of proenzymes and the 
inhibition of MMPs by TIMPs are 
important regulatory processes. MMPs 
are secreted in a latent form as pro-
MMPs, which require activation. In 
the propeptide domain of the MMPs, 
a cysteine residue (Cys73) is present, 
which functions as a stabilizer of 
the inactive proenzyme 
(27,28). In the catalytic 
domain, an active Zn2+ site 
is present, which forms 
a bond with the cysteine 
residue. When this Cys73-
Zn2+ bond is intact, the 
MMP is inactive (Figure 
1). The activation of MMPs 
involves a disruption of the 
bond between the active 
Zn2+ site and the cysteine 
residue. This mechanism 
has been referred to as 
the “cysteine switch” 
(27,28). A water molecule 
then binds to the Zn2+ ion 
and replaces the cysteine 
residue after the dissoci-
ation (27). The noncatalytic 
zinc is then switched to a 
catalytic one, which results 
in an intermediate active 
enzyme (27). Additionally, 
the pro-domain of the 
MMP is removed by 
autolytic cleavage or by 
other proteases (27,28). 
This cleavage causes a 
reduction in molecular 
mass and results in a fully 
active enzyme. The mass reduction 
is generally in the range of 8–10 kDa 
(29). In vivo, MMPs are generally 
activated by other proteinases. In vitro, 
MMPs are also activated by chemical 
and physical agents such as amino-
phenylmercuric acetate (APMA), low 
pH, and heat treatment (12,15,27).
THE ROLE OF MMPs IN 
NORMAL TISSUE REMODELING
MMP activity is mainly regulated 
by TIMPs, of which four human forms 
are known that can inhibit almost all 
MMPs tested thus far. Moreover, the 
TIMPs do not seem to differentiate 
much between the various MMPs 
(4,12). TIMPs have a high level of 
sequence heterogeneity, which suggests 
that they also have different functional 
properties (2). For instance, in addition 
to inhibiting MMP activity, TIMPs also 
seem to have growth factor-like and 
antiangiogenic properties (30). TIMPs 
generally inhibit the activity of MMPs 
by the formation of a 1:1 complex (12). 
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Table 1. Members of the MMP Family 
Subgroup MMP Name Substrate
1. Collagenases MMP-1
MMP-8
MMP-13
Collagenase-1
Collagenase-2 
Collagenase-3
Col I, II, III, VII, VIII, X, gelatin
Col I, II, III, VII, VIII, X, aggrecan, gelatin
Col I, II, III, IV, IX, X, XIV, gelatin
2. Gelatinases MMP-2
MMP-9
Gelatinase A
Gelatinase B
Gelatin, Col I, II, III, IV, VII, X
Gelatin, Col IV, V
3. Stromelysins MMP-3
MMP-10
MMP-11
Stromelysin-1
Stromelysin-2
Stromelysin-3
Col II, IV, IX, X, XI, gelatin
Col IV, laminin, fibronectin, elastin
Col IV, fibronectin, laminin, aggrecan
4. Matrilysins MMP-7
MMP-26
Matrilysin-1
Matrilysin-2
Fibronectin, laminin, Col IV, gelatin
Fibrinogen, fibronectin, gelatin
5. MT-MMP MMP-14
MMP-15
MMP-16
MMP-17
MMP-24
MMP-25
MT1-MMP
MT2-MMP
MT3-MMP
MT4-MMP
MT5-MMP
MT6-MMP
Gelatin, fibronectin, laminin
Gelatin, fibronectin, laminin
Gelatin, fibronectin, laminin
Fibrinogen, fibrin
Gelatin, fibronectin, laminin
Gelatin  
6. Others MMP-12
MMP-19
MMP-20
MMP-21
MMP-23
MMP-27
MMP-28
Macrophage metalloelastase
Enamelysin
XMMP 
CMMP 
Epilysin
Elastin, fibronectin, Col IV 
Aggrecan, elastin, fibrillin, Col IV, gelatin
Aggrecan
Aggrecan
Gelatin, casein, fibronectin
Unknown
Unknown
MMPs are categorized according to the organization of their peptide domains, their substrate specificity, and their se-
quence similarity (8,12,17,22–24,85–87). MMP, matrix metalloproteinase; MT-MMP, membrane-type matrix metallopro-
teinase.
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Normal and pathological tissue remod-
eling is regulated by the balance of 
MMPs and TIMPs within the tissue (4). 
The remodeling of tissues is essential 
for several aspects of normal physi-
ology, including embryonic devel-
opment, collagen turnover, tooth devel-
opment, and cell migration but also in 
processes like wound healing (5–7). 
For instance, during the embryonic 
development in mice, mRNA levels for 
MMP-9 and MMP-13 and TIMP-1 are 
highly expressed in bone. Additionally, 
in embryonic epithelial tissues, mRNA 
for TIMP-3 is widely expressed (6).
THE ROLE OF MMPs IN 
PATHOLOGICAL TISSUE 
REMODELING
Numerous pathological conditions 
are caused by the disruption of the 
balance between MMPs and TIMPs 
(4). Overproduction of MMPs is 
associated with tissue destruction in 
chronic inflammatory diseases such as 
rheumatoid and osteoarthritis (9,10). 
In both conditions, it appears that the 
erosion of cartilage is caused by an 
increased expression of MMPs such 
as MMP-1, MMP-8, and MMP-13, 
depending on the joint tested (9,10). In 
addition, the contribution of each MMP 
to the disease process may vary in each 
joint (31). MMPs are also involved in 
tumor growth and metastasis (32). In 
almost all human cancers, the MMP 
expression and activity are increased. 
In colon cancer, mainly MMP-7 is 
overexpressed (33,34). The increased 
levels of MMPs seem to correlate with 
invasiveness and poor prognosis (16). 
Deregulation of MMPs has also been 
implicated in distinct acute and chronic 
cardiovascular diseases, such as athero-
sclerosis, myocardial infarction, and 
heart failure (35,36). Several MMPs 
such as MMP-1 and MMP-9 are also 
known to influence the process of 
atherosclerotic lesion formation, but 
the mechanism is still not completely 
elucidated (22). 
Many different MMPs are involved 
in normal tissue remodeling but also 
play a role in tissue resorption in patho-
logical conditions. To prevent tissue 
degradation by a disturbed MMP-
TIMP balance, it is important to know 
which MMPs and TIMPs are involved 
in the specific disease processes. Thus, 
the analysis of MMPs in biological 
samples can contribute to the charac-
terization of certain diseases involving 
tissue destruction and possibly to the 
development of new therapies. 
DETECTION OF MMPs
The expression of MMPs can be 
analyzed with several techniques. A 
widely used technique is substrate 
zymography, which identifies MMPs 
by the degradation of their preferential 
substrate and by their molecular weight. 
Using this technique, one can determine 
whether the MMP is in an active or 
latent form. To localize MMPs in tissue 
sections, in situ zymography can be 
performed. TIMPs can be detected by 
reverse zymography, which is based 
on their ability to inhibit MMPs. These 
specific techniques will be discussed in 
the next sections.
SUBSTRATE ZYMOGRAPHY
Zymography and reverse zymog-
raphy are described as simple, 
sensitive, quantifiable, and functional 
assays to analyze MMPs and TIMPs 
in biological samples (37,38). All 
types of substrate zymography 
originate from gelatin zymography. 
The techniques are the same except 
that the substrate differs depending 
on the type of MMPs or TIMPs to be 
detected. In zymography, the proteins 
are separated by electrophoresis under 
denaturing [sodium dodecyl sulfate 
(SDS)], nonreducing conditions. The 
separation occurs in a polyacrylamide 
gel containing a specific substrate that 
is co-polymerized with the acrylamide 
(39,40). During electrophoresis, the 
SDS causes the MMPs to denature 
and become inactive. The activation 
of latent MMPs during zymography 
is believed to involve the “cysteine 
switch” because the dissociation of 
Cys73 from the zinc molecule is caused 
by SDS (Figure 1; Reference 27). After 
electrophoresis, the gel is washed, 
which causes the exchange of the SDS 
with Triton® X-100, after which the 
enzymes partially renature and recover 
their activity (39,41). Additionally, the 
latent MMPs are autoactivated without 
cleavage (42). Subsequently, the gel is 
incubated in an appropriate activation 
buffer. During this incubation, the 
concentrated, renatured MMPs in the 
gel will digest the substrate (37,40). 
After incubation, the gel is stained with 
Coomassie® Blue, and the MMPs are 
detected as clear bands against a blue 
background of undegraded substrate 
(37,40). The clear bands in the gel can 
be quantified by densitometry (41). 
Zymography is based on the following 
principles: (i) during electrophoresis, 
gelatin is retained in the gel; (ii) MMP 
activity is reversibly inhibited by SDS 
Figure 1. The activation of pro-MMPs. The 
activation of latent MMPs involves a disruption 
of the Cys73-Zn2+ bond that results in an inter-
mediate active form. During zymography, the 
latent MMP unfolds due to SDS. The fully active 
MMP form is formed in vivo through proteolysis 
(27,28). MMP, matrix metalloproteinase; SDS, 
sodium dodecyl sulfate.
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during electrophoresis; and (iii) the 
SDS causes the separation of MMP-
TIMP complexes during electropho-
resis. This enables the detection of 
MMPs and TIMPs independently 
of one another (37). An additional 
advantage of zymography is that both 
the proenzymes and the active forms 
of MMPs can be distinguished on the 
basis of their molecular weight (41). 
As mentioned before, SDS dissociates 
the TIMPs from the MMPs, which may 
result in a higher activity than in vivo. 
Because zymography only indicates 
whether the proenzyme displays in the 
presence of TIMP in vivo, it is uncertain 
how much activity such an active form 
would display in the presence of TIMP 
in vivo (41). Additionally, the refolding 
of MMPs after electrophoresis recovers 
only part of the original activity. 
Furthermore, the digestion of gelatin 
by pro-MMPs is somewhat reduced 
because the latent form still retains its 
propeptide domain (41).
Gelatin Zymography
Gelatin zymography is mainly used 
for the detection of the gelatinases, 
MMP-2 and MMP-9, respectively 
(Figure 2). It is extremely sensitive 
because levels of 10 pg of MMP-2 can 
already be detected (43). It should be 
considered, however, that other MMPs, 
such as MMP-1, MMP-8, and MMP-13 
can also lyse the substrate. This signal 
will probably be very weak because 
gelatin is not their preferential substrate 
(44,45). For MMPs that do not show 
any activity on gelatin, modifications 
of the technique have been made for 
an improved detection. This is mainly 
done by incorporating a more suitable 
substrate into the gel, such as casein 
or collagen, or by enhancing the signal 
by adding heparin to the samples 
(40,46,47).
Casein Zymography
Casein is a preferential substrate for 
the stromelysins including MMP-11, 
however, the native forms of MMP-11 
show no caseinolytic activity (48–52). 
Casein zymography is also suitable 
for the detection of MMP-1, MMP-7, 
MMP-12, and MMP-13 (53–56). In 
addition, MMP-9 can be detected when 
present in high concentrations. Unfor-
tunately, casein zymography is much 
less sensitive than gelatin zymog-
raphy. Furthermore, casein migrates 
in the gel during electrophoresis due 
to its relatively low molecular weight 
(23 kDa). This results in two clearly 
defined zones in the gel, the lower 
part that still contains excess casein 
and the upper part with less casein. 
The anodic migration of the casein 
is especially problematic in the case 
of MMPs that end up near the casein-
migration boundary, such as the latent 
and activated forms of MMP-7 (29 and 
20 kDa, respectively; Reference 40). 
Prerunning the casein gel, allowing 
the excess casein to migrate out, can 
solve this. A second run of the gel 
does not cause any further migration 
of the casein, therefore eliminating its 
interference with the MMP bands. The 
amount of casein remaining in the gel 
is still sufficient for the detection of 
MMPs. According to the literature, the 
minimal detectable amount of purified 
recombinant MMP-7 is 1 ng, but 8 ng 
and more will give clear bands (40). 
Collagen Zymography
Collagen zymography is mainly 
used for the detection of MMP-1 and 
MMP-13, but MMP-2 and MMP-9 can 
also be detected (45,57,58). The incor-
poration of native collagen fibers in 
polyacrylamide gels appears unsuitable 
for zymography because of their 
complicated structure, but SDS disrupts 
most of the fibrillar organization of the 
collagen, allowing proteins to run into 
the gel. After running the zymogram, 
the exchange of SDS and Triton X-100 
during incubation restores part of the 
original triple-helical conformation 
of collagen, allowing its degradation 
by collagenases. In collagen zymog-
raphy, amounts of 10 pg of pro-MMP-
1 and 0.1 pg of active MMP-1 can be 
detected (47). The band intensity of 1 
pg of active MMP-1 is about equivalent 
to that of 22 pg of pro-MMP-1. This 
indicates the necessity to calibrate the 
signal of the pro-MMP-1 and active 
MMP-1 for accurate quantification 
(47).
Heparin-Enhanced Substrate 
Zymography 
MMP-7 and the collagenases are 
hard to detect at low levels in casein 
or gelatin zymography. It is possible 
to detect MMP-7 in carboxymeth-
ylated (CM) transferrin zymography, 
which is occasionally used, but often 
the signal is very low (59–61). It is 
known that the extraction of MMPs 
from tissue in the presence of heparin 
results in an enhancement of MMP 
activity. The addition of heparin to 
the samples during or prior to electro-
phoresis also enhances MMP activity. 
The signal of intermediate and active 
MMP-7 can be enhanced about 5-fold 
by heparin in CM transferrin zymog-
raphy and the detection of pro-MMP-7 
can be enhanced even 20-fold (46,61). 
The mechanisms by which heparin 
seem to enhance MMP-7 activity in 
Figure 2. Gelatin zymography. MMPs are extracted from periodontal ligament, which is the ligament 
surrounding the root of a tooth, by three homogenization steps (lanes 1–3) and two heat extraction steps 
(lanes 4 and 5). Several MMPs are indicated such as MMP-1, MMP-2, and MMP-9. In addition, some 
complexes of MMPs are detected. The molecular weight standards [(Mw) Broad Range Marker; Bio-
Rad Laboratories, Hercules, CA, USA] are indicated (M.M. Bildt and P.A.M. Snoek-van Beurden, un-
published data). MMP, matrix metalloproteinase. 
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zymography are (i) the induction of a 
conformational change, (ii) the facili-
tation of refolding, (iii) the reduction 
of autolysis, or (iv) the increase of 
anchorage of the MMP in the gel (61). 
In the case of pro-MMP-7, heparin-
enhanced CM transferrin zymography 
can detect as little as 30 pg/lane 
compared to about 750 pg without 
heparin. It is also possible to enhance 
the activity of MMP-1 and MMP-13 in 
gelatin zymography by adding heparin, 
which increases the sensitivity at least 
5-fold (46).
The heparin forms a wide band 
or “heparin box” in the gel that spans 
a region of about 15–30 kDa, thus 
covering the MMP-7 forms with a 
molecular weight of 19 and 28 kDa 
(Figure 3A) (46). Only when the 
MMPs end up in the heparin box, the 
enhancement is optimal. To determine 
the location of the heparin box, a 
separate regular sodium dodecyl 
sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) gel must be run, on 
which heparin can be detected with 
an azure A staining for glycosamino-
glycans. Because the active and latent 
forms of MMP-1 and MMP-13 are in 
the range of 40–60 kDa, heparin should 
be added to the lanes 20–30 min after 
the start of electrophoresis to ensure the 
co-migration of the MMPs and heparin 
(46). Prestained molecular weight 
standards are also added together with 
the heparin to indicate its position. For 
instance, when the 31-kDa band of the 
secondary molecular weight standards 
line up with the 66 kDa band of the 
primary molecular weight standards, 
the heparin box will fall in the range 
36–66 kDa of the first molecular 
weight standards (Figure 3B; Reference 
46). In conclusion, it is important to 
position the heparin box correctly to 
achieve reliable results. This makes the 
method more complex than other, more 
common forms of zymography.
Reverse Zymography
Four human TIMPs are known 
of which only TIMP-3 occurs in a 
glycosylated and an unglycosylated 
form. They can be detected by reverse 
zymography, which is a modification of 
zymography for MMPs (37). Besides 
gelatin, an MMP is also incorporated 
into the gel, usually MMP-2. During 
the activation step after electrophoresis, 
the MMP-2 only digests the gelatin 
in areas where TIMPs are absent. 
Thus, after staining, the gel will be 
colorless, except for the TIMP bands. 
In these bands, the TIMPs will inhibit 
MMP-2 activity by the formation of a 
1:1 complex, and the gelatin will not 
be digested (62,63). This results in 
blue TIMP bands against a colorless 
background (37). The SDS in the gel 
dissociates any TIMPs bound to MMPs, 
and thus the total amount of TIMPs in 
the sample is detected (63). 
The cheapest way to perform 
reverse zymography is to incorporate 
conditioned medium with MMPs 
in the gel next to gelatin (62). The 
conditioned medium should contain 
MMP-2 because all known TIMPs 
inhibit MMP-2 effectively (37). It is 
also possible to incorporate purified 
MMP-2, but this is far more expensive 
(64). A typical reverse zymogram with 
incorporated purified MMP-2 shows 
two sections, a small upper section 
(section 1) and a wider middle section 
(Figure 4A, section 2 and Figure 4C; 
Reference 42). Section 1 contains no 
MMP-2 because it is migrated further 
into the gel. This section is therefore 
stained blue because of the presence 
of gelatin. Thus, in this section, it is 
possible to detect MMP activity (42). 
Section 2 contains the MMP-2 and can 
be used for the detection of TIMPs (37). 
It is also possible to use conditioned 
medium that contains both MMP-2 and 
TIMP-2 activity. Due to the presence of 
SDS, the MMP-TIMP complexes in the 
conditioned medium will dissociate, 
and both will migrate through the gel 
according to their molecular weights 
(72 and 20 kDa, respectively; Reference 
37). This results in three distinct 
sections on the Coomassie blue-stained 
gel, a narrow upper section (section 1), 
a wide middle section (section 2), and 
a narrow lower section (Figure 4B, 
section 3 and Figure 4D; References 
37 and 42). Section 1 contains neither 
MMP-2 nor TIMP-2. Section 2 contains 
only MMP-2, while TIMP-2 has 
migrated further downwards because of 
its smaller molecular weight. Section 
3 contains MMP-2 and the remaining 
TIMP-2. Section 2 is the analytical part 
of the gel and is used for the detection 
of TIMP activity (37,62). 
To obtain an increased effective 
range of the analytical section, the 
electrophoresis time can be prolonged. 
Furthermore, a longer stacking gel 
will increase the distance between any 
TIMP-2 from the sample and the TIMP-
2 from the conditioned medium (37). It 
is not recommended to use conditioned 
medium that contains other TIMPs 
than TIMP-2, such as TIMP-1 (28 
kDa), because its lower electrophoretic 
mobility yields a narrower analytical 
range in the gel (37). When condi-
tioned medium is used that contains 
Figure 3. Heparin-enhanced zymography. The heparin box (light gray) must overlap the MMPs to 
enhance their activity. (A) The heparin box when heparin is added together with the samples and the 
primary standard (Mw1). (B) The heparin box when heparin is added after the start of electrophoresis 
together with the secondary standard (Mw2). The dark gray bands represent the molecular weight stan-
dards (Mw). MMP, matrix metalloproteinase.
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several MMPs, the background staining 
will consist of a pattern of horizontal 
regions, which renders the analysis of 
TIMPs inaccurate (42). 
For the analysis of a reverse 
zymogram, it is necessary to discrim-
inate between the TIMP bands and 
the proteins that are present in the 
sample, which will also be stained by 
the Coomassie Blue (37). Therefore, 
extracted tissue samples and total 
cell lysates from cultured cells can 
be particularly problematic. To avoid 
interference by endogenous proteins, 
samples should be electrophoresed at 
dilutions that do not allow detection 
of these proteins. Thus, a regular 
SDS-PAGE gel with the same sample 
should be run under identical condi-
tions (37). Bands that appear in the 
reverse zymogram and are not visible 
in the regular SDS gel must be TIMPs 
(37). To obtain a reliable reverse 
zymogram, optimization of the gelatin 
and gelatinase concentration is required 
because this can dramatically increase 
the sensitivity (42). Recently, real-
time zymography and reverse zymog-
raphy were developed, which use a 
fluorescein isothiocyanate (FITC)-
labeled substrate (65). With these 
techniques, the substrate degradation 
can be monitored continuously with a 
transilluminator. Another advantage is 
the higher sensitivity that is achieved 
with lower amounts of substrates (65). 
In Situ Zymography
In situ zymography allows the 
localization of MMPs in tissue sections 
(26,66,67). It is an adaptation of 
substrate zymography that is suitable 
for frozen sections. The nature of the 
substrate dictates which MMP can be 
detected (68). In situ zymography is 
a relatively low-cost technique (68). 
Briefly, in situ zymography uses a 
substrate that is deposited on or under 
a frozen section of an unfixed tissue 
sample (Figure 5; Reference 68). During 
incubation, the substrate will be digested 
by the activated MMPs in a time- and 
dose-dependent manner (68). The 
degradation of the substrate is detected 
by light microscopy or fluorescence 
microscopy, depending on the type of 
substrate. For instance, gelatinolytic 
activity can be detected using a gelatin-
containing photographic emulsion that 
is mixed with MMP activation buffer. 
MMPs present in the section can be 
detected due to exposure to ambient 
light during incubation and the subse-
quent photographic processing. The 
emulsion contains light-sensitive silver 
halide crystals that are evenly dispersed 
by gelatin. Photographic chemicals are 
allowed to reach the crystals when gelatin 
is not degraded by MMPs. This results 
in a chemical change of the crystals, 
leading to a black image. Chemicals 
are unable to penetrate the emulsion on 
spots where the gelatin is degraded, and 
white spots will appear. In conclusion, 
the MMP activity can be determined 
by light microscopy as white spots on 
a black background of undegraded 
substrate (Figure 5A; Reference 26). 
When using a fluorescent substrate, the 
degradation of the substrate causes loss 
of fluorescence, and the MMPs are then 
detected as black spots on a fluorescent 
background (Figure 5B; Reference 26). 
A more sensitive modification of this 
method uses a quenched fluorogenic 
substrate (69). When this substrate is 
cleaved, the MMPs are detected as 
strong fluorescent spots against a black 
background (Figure 5C; Reference 70). 
With in situ zymography, only active 
MMPs are detected, but by activating 
latent MMPs (i.e., with APMA), both 
forms are visible (71). A limitation of 
this technique is that it may be difficult 
to discriminate between the different 
Figure 4. Reverse zymography. Overviews and examples of reverse zymography under different con-
ditions. (A) An overview of a reverse zymogram with incorporated gelatin and purified MMP-2. Black 
bands represent TIMP activity. Section 1 contains only gelatin, and section 2 contains MMP-2 and di-
gested gelatin. (B) An overview of a reverse zymogram with incorporated gelatin and conditioned me-
dium containing both MMP-2 and TIMP-2. Black bands represent TIMP activity. Section 1 contains 
only gelatin, and section 2 contains MMP-2 and digested gelatin. Section 3 contains gelatin, MMP-2, 
and TIMP-2 that have not migrated out of the gel. (A and B) Section 2 is used for the detection of 
TIMPs, which are visible as blue bands against a colorless background. (C) An example of reverse zy-
mography with incorporated gelatin and purified MMP-2 showing TIMP-1. [Reprinted from Analytical 
Biochemistry, 244, Oliver et al., Quantitative reverse zymography: analysis of picogram amounts of 
metalloproteinase inhibitors using gelatinase A and B reverse zymograms, p. 161-166, copyright (1997), 
with permission from Elsevier (42)]. (D) An example of reverse zymography with incorporated gelatin 
and conditioned medium containing both MMP-2 and TIMP-2 showing both the glycosylated and un-
glycosylated form of TIMP-3. [Reprinted with permission from Hawkes et al., Zymography and reverse 
zymography for detecting MMPs, and TIMPs, p. 399-410. In I. Clark (Ed.), Matrix Metalloproteinases 
Protocols. Humana Press, Totowa, NJ, 2001 (37)]. MMP, matrix metalloproteinase; TIMPs, tissue in-
hibitors of metalloproteinases.
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classes of MMPs (68). Additionally, 
not only can MMPs break down the 
substrates, but also serine, cysteine, or 
aspartic proteinases. Thus, it is essential 
to use control slides with appropriate 
MMP inhibitors (66). The main obstacle 
for in situ zymography is the scarcity 
of specific substrates or specific inhib-
itors, although more and more of these 
substrates and molecules will become 
available. A relatively new substrate is a 
biocompatible near-infrared fluorogenic 
(NIRF) MMP probe, consisting of a 
quenched near-infrared fluorochrome 
and an MMP-2 substrate on a nonim-
munogenic backbone (72). When the 
substrate is cleaved, which occurs 
preferentially by MMP-2, the fluores-
cence intensity increases significantly. 
The probe can be used in live animals 
and can detect MMP activity within 
hours after injection (72). After placing 
the animal in a light-tight chamber, the 
fluorogenic activity inside the animal 
can be visualized with an imaging 
system (73). This technique has been 
developed to monitor MMP activity and 
their inhibition in tumors in vivo (72). 
For the specific detection and imaging 
of MMP-7 in tumors, the polymer-based 
fluorogenic substrate PB-M7VIS has 
been developed (74). 
Other new in situ zymography 
techniques are being developed, which 
have been named three-dimensional (3-
D), 4-D, and 5-D in situ zymography 
(75–77). In the 3-D technique, collagen 
with a quenched fluorescent label is co-
polymerized together with the cells in 
a 3-D collagen lattice. The degradation 
of collagen by MMPs from live cells is 
detected by measuring the fluorescent 
signal with confocal microscopy 
(76,77). The monitoring of the signal in 
the collagen lattices over time produces 
a 4-D technique (77). The use of more 
than one fluorochrome to determine the 
localization of several MMPs in time 
generates 5-D information (http://www.
ichc2004.org/PdfFolder/AbstractsAu-
thorIndex.pdf; SP8). The advantages 
of these techniques over normal in 
situ zymography are the possibility to 
monitor cell migration and cell shape 
changes in addition to the progression 
of substrate degradation (75–77).
PROBLEMS 
MMP Extraction
In media obtained from cell culture, 
it is relatively easy to detect MMPs and 
TIMPs. However, the extraction and 
analysis of MMPs and TIMPs from 
tissues are much more difficult. In the 
first place, the amount of MMPs and 
TIMPs in tissues is about 50 times 
lower than those found in conditioned 
medium (41). Secondly, they are 
difficult to extract from tissues, and 
it is never certain whether all MMPs 
and TIMPs are extracted. Moreover, 
several MMPs, such as MMP-1, MMP-
2, and MMP-9, are tightly bound to 
the ECM (41). Another disadvantage 
of tissue extraction is the preclusion of 
the localization of MMPs. In addition, 
the extraction procedure can activate 
MMPs, but MMPs can also be inacti-
vated by binding with their respective 
inhibitors, which may have been 
localized in distinct compartments in 
the intact cells or tissue (68). Specific 
MMPs or TIMPs localized in a small 
Figure 5. In situ zymography. An overview and an example of in situ zymography are shown. In situ zymography using (A) a photographic emulsion and (B) a 
fluorescent substrate. (C) An example of in situ zymography using quenched fluorogenic gelatin. MMP activity is shown as green fluorescence, and the section 
is counterstained with DAPI (70). (D) The red signal indicates the immunolocalization of MMP-2. It shows a similar localization pattern as the fluorescent sig-
nal in Figure 5C, indicating that the gelatin degradation is caused by MMP-2. The section is counterstained with DAPI. [Figure 5, C and D, is reproduced with 
permission from Mook et al., In situ localization of gelatinolytic Activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched 
fluorogenic DQ-gelatin. Journal of Histochemistry and Cytochemistry 51:821-829, 2003 (70)]. MMP, matrix metalloproteinase.
80 BioTechniques Vol. 38, No. 1 (2005)
REVIEW
part of the tissue may not be detected 
because of its dilution in the entire 
tissue extract (68). Because of these 
problems, it is difficult to determine the 
actual activity of MMPs in tissues. To 
localize MMPs in tissue in the presence 
of TIMPs, using in situ zymography is 
recommended. This technique reflects 
the endogenous balance of MMPs and 
TIMPs in the tissue, although quantifi-
cation is not possible (68). 
Substrate Zymography
Sample preparation is very important 
when performing a zymography. The 
samples should not be boiled because the 
MMPs will lose their activity. Moreover, 
the addition of β-mercaptoethanol to 
the sample buffer is not recommended 
because it breaks the disulphide bonds 
of the MMPs. After the zymography, 
the MMPs will not be able to refold 
again, which causes a dramatic decrease 
in their activity (37). It should be 
considered that the nonreducing condi-
tions lead to slightly different migration 
characteristics of the MMPs and TIMPs 
compared with Western blot analysis 
(37). It is also important to consider that 
SDS dissociates MMPs from TIMPs, 
and thus only indicates the presence of 
MMPs and TIMPs, but not the actual 
activity within the tissue. 
The staining and destaining of the 
zymogram can lead to overstaining, 
which causes loss of sensitivity. Alter-
natively, it is possible to destain the gel 
too much, which bleaches the bands and 
makes them unsuitable for quantification 
(38). Simply combining the staining 
and destaining solutions can solve this 
problem. It will also yield a fast and repro-
ducible staining (38). This single-step 
staining protocol was successfully used 
for the analysis of MMP-2 and MMP-9 
in gelatin zymography and for MMP-
7 in casein zymography (38). Testing 
substrates from various sources might 
further increase the sensitivity of zymog-
raphy or reverse zymography. Substrates 
can differ considerably in performance, 
especially in reverse zymography (37). 
For every new substrate, it is necessary to 
determine the optimal substrate concen-
tration, the most suitable conditioned 
medium, and the optimal running and 
developing conditions (37,42). Despite 
the optimization, specific MMPs might 
still not be detected because zymography 
is sometimes just not sensitive enough. In 
those cases, other assays might be more 
suitable, such as enzyme-linked immuno-
sorbent assay (ELISA) or Western 
blot analysis. For example, MMP-8 is 
difficult to detect with zymography, but 
with other techniques it might be possible 
to measure protein levels (78,79).
In situ zymography is used for the 
identification and microscopic local-
ization of MMPs within sections of 
unfixed frozen tissues. The MMPs are 
detected using a photographic emulsion or 
a fluorescent substrate. A disadvantage of 
the photographic method is the difficulty 
to standardize the method (80). The slides 
cannot be coverslipped and are therefore 
more sensitive to variations in humidity 
during the incubation. Additionally, the 
thickness of the emulsion layer might be 
uneven and thereby reduce the quality 
of the results (80). In contrast, with the 
fluorescent substrate, the substrate is 
deposited on the slide before applying the 
section. In this way, poorly coated glass 
slides can be detected by microscopic 
inspection before placing the tissue 
sections on the slides (80). However, 
the sensitivity of this method is lower 
because higher levels of enzymatic 
activity are required to produce spots 
large enough for detection (68). A more 
sensitive approach, which is often used 
nowadays, uses a highly quenched 
fluorescent substrate that fluoresces only 
after degradation. The enzymatic activity 
is observed as a fluorescent area against a 
darker, low fluorescent background (69).
PROBLEMS WITH THE 
ANALYSIS
The identification of MMPs and 
TIMPs is often achieved by comparison 
with known molecular weight standards 
(37). One should be aware that some 
commercially available molecular 
weight standards contain a reducing 
agent. When these standards are used 
under nonreducing conditions, they may 
indicate different molecular weights (37). 
For a definite identification of MMPs 
and TIMPs, one must perform Western 
blot analysis using specific antibodies. 
Because zymography is much more 
sensitive than Western blot analysis, 
it might be difficult to find antibodies 
that are sensitive enough to detect small 
amounts of MMPs and TIMPs. 
MMPs and TIMPs can be quantified 
after zymography using densitometry. 
The amounts of MMPs or TIMPs are 
determined by comparison with a 
standard curve of a purified enzyme 
(47). However, complexes of MMPs 
might occur that complicate the 
analysis. MMP-9 can be associated 
with a 25-kDa protein (microglobulin), 
giving a band at 125 kDa and a dimer 
at 215 kDa. These complexes are not 
dissociated in zymography (81). In 
Figure 2, a band is found at 240 kDa 
that might represent a multimer or 
pro-MMP-9 (82). Also, several MMPs 
together can form complexes that 
can only be identified with specific 
antibodies in Western blot analysis. 
Using in situ zymography, it is often 
not possible to discriminate between 
different MMPs because the substrates 
are usually degraded by more than 
one MMP. Specific MMPs should be 
identified by a complementary technique 
such as immunohistochemistry for valid 
conclusions (68). The immunolocal-
ization of MMPs can be compared with 
the localization pattern of the in situ 
zymography, which should be preferably 
performed on the same section or on 
serial sections (66). Some very specific 
substrates for MMP-1, MMP-7, MMP-
8, and MMP-13 are currently available, 
which are generally fluorescent peptides 
(45,83,88). To summarize, although 
the limitations of the zymographical 
techniques make it sometimes difficult to 
interpret the data, it is the most suitable 
technique to analyze MMPs. 
CONCLUSION
The balance between MMPs and 
TIMPs regulates tissue remodeling 
under normal conditions. A deregu-
lation of this balance is a characteristic 
of pathological conditions involving 
extensive tissue degradation. To 
analyze the role of various MMPs and 
TIMPs under normal and pathological 
conditions, reliable detection methods 
such as zymography are required. This 
technique is a highly sensitive method 
for the analysis of MMPs and TIMPs. 
Various adaptations of substrate 
zymography are currently available, 
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which are generally cheap and easy to 
perform. Most of these methods are 
very sensitive, but this also depends on 
the specific MMP or TIMP under study. 
Optimization of the subsequent steps 
is necessary to obtain high sensitivity 
and accuracy. Additionally, modifica-
tions are being developed that may lead 
to faster and more reliable techniques 
such as the real-time dual zymography 
in which fluorescent gelatin and casein 
are incorporated in the same gel (84). 
For in situ zymography, newer and more 
sensitive substrates are being developed 
to discriminate between the different 
MMPs. The improvement of sensi-
tivity and accuracy of zymographical 
methods will further enhance its value 
for research purposes and for the devel-
opment of new diagnostic techniques 
and therapies for conditions that involve 
extensive tissue degradation.
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